CAS: 304000-05-3
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | (4E)-2-(3,4-dimethoxyphenyl)-4-[(pyridin-3-yl)methylidene]-4,5-dihydro-1,3-oxazol-5-one REF: IN-DA01WAUCCAS: 304000-05-3 | 98% | To inquire | Thu 14 Nov 24 |
 | DAPK-IN-2 REF: TM-T77611CAS: 304000-05-3 | 98.26% | 91.00 €~2,009.00 € | Fri 15 Nov 24 |
![(4E)-2-(3,4-dimethoxyphenyl)-4-[(pyridin-3-yl)methylidene]-4,5-dihydro-1,3-oxazol-5-one](https://static.cymitquimica.com/products/IN/thumb/DA01WAUC.jpg)
(4E)-2-(3,4-dimethoxyphenyl)-4-[(pyridin-3-yl)methylidene]-4,5-dihydro-1,3-oxazol-5-one
CAS:304000-05-3
Formula:
C17H14N2O4
Purity:
98%
Molecular weight:
310.3041
Ref: IN-DA01WAUC
| 5mg | 145.00 € | ||
| 10mg | 243.00 € | ||
| 25mg | 547.00 € | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Estimated delivery in United States, on Thursday 14 Nov 2024
DAPK-IN-2
CAS:304000-05-3
DAPK-IN-2: DAPK inhibitor with anticancer potential. Used in cerebral infarction and ischemia research.
Formula:
C17H14N2O4
Purity:
98.26%
Color and Shape:
Liquid
Molecular weight:
310.3
Ref: TM-T77611
| 1mg | 91.00 € | ||
| 2mg | 134.00 € | ||
| 5mg | 215.00 € | ||
| 10mg | 335.00 € | ||
| 25mg | 558.00 € | ||
| 50mg | 742.00 € | ||
| 100mg | 1,009.00 € | ||
| 500mg | 2,009.00 € |
Estimated delivery in United States, on Friday 15 Nov 2024
